Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 19

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 19
---
 pipeline of investment capital and increases the risk profile of the Company If Deep Track Truly Wanted to Fix the Company, It is Five Years Too Late 27 | Deep Track’s “Plan” Consequences © Copyright DYNAVAX 2025 But Deep Track is not here to fix the Company. It is pursuing a singular short - term agenda to benefit Deep Track at the expense of other stockholders.

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx 203 % 0 % 100 % 200 % 300 % 400 % 500 % 600 % Apr-2020 Apr-2021 Apr-2022 Apr-2023 Apr-2024 Apr-2025 Indexed TSR 203 % (17)% 9 % Dynavax S&P Biotechnology Select Industry Index (XBI) Vaccine Peers 145 % 21 % 68 % Dynavax S&P Biotechnology Select Industry Index (XBI) Vaccine Peers 28 | An honest analysis clearly demonstrates we have outperformed the market and our peers over an extended period Deep Track Distorts the Facts to Fit its Narrative About Our Performance © Copyright DYNAVAX 2025 Five - Year Total Stockholder Return 1 Source: FactSet; Market data as of 17 - Apr - 2025 1 Total stockholder return as of 17 - Apr - 2025. 2 Vaccine Peers comprised of Bavarian Nordic, Emergent BioSolutions, Novavax, Valneva, and Vaxcyte; Vaxcyte TSR from IPO on 12 - Jun - 2020 to pricing date, 17 - Apr - 2025. • Intentionally leverages a temporary spike in our share price in late October 2021, driven by momentum from COVID - 19 related CpG - 1018 sales, to focus on an unflattering 3 - year lookback • Uses this deceptive analysis to attack the tenure of our Chairman, who happened to be appointed to the Board on Oct. 21, 2021 Deep Track claims a TSR start date of Oct. 24, 2024 (its amended 13D filing), which: 5 - year TSR Through 16 - Sep - 2024 (Initial Deep Track 13D